Cargando…

PPARs at the crossroads of T cell differentiation and type 1 diabetes

T-cell-mediated autoimmune type 1 diabetes (T1D) is characterized by the immune-mediated destruction of pancreatic beta cells (β-cells). The increasing prevalence of T1D poses significant challenges to the healthcare system, particularly in countries with struggling economies. This review paper high...

Descripción completa

Detalles Bibliográficos
Autores principales: Riaz, Farooq, Wei, Ping, Pan, Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623333/
https://www.ncbi.nlm.nih.gov/pubmed/37928539
http://dx.doi.org/10.3389/fimmu.2023.1292238
_version_ 1785130720144916480
author Riaz, Farooq
Wei, Ping
Pan, Fan
author_facet Riaz, Farooq
Wei, Ping
Pan, Fan
author_sort Riaz, Farooq
collection PubMed
description T-cell-mediated autoimmune type 1 diabetes (T1D) is characterized by the immune-mediated destruction of pancreatic beta cells (β-cells). The increasing prevalence of T1D poses significant challenges to the healthcare system, particularly in countries with struggling economies. This review paper highlights the multifaceted roles of Peroxisome Proliferator-Activated Receptors (PPARs) in the context of T1D, shedding light on their potential as regulators of immune responses and β-cell biology. Recent research has elucidated the intricate interplay between CD4+ T cell subsets, such as Tregs and Th17, in developing autoimmune diseases like T1D. Th17 cells drive inflammation, while Tregs exert immunosuppressive functions, highlighting the delicate balance crucial for immune homeostasis. Immunotherapy has shown promise in reinstating self-tolerance and restricting the destruction of autoimmune responses, but further investigations are required to refine these therapeutic strategies. Intriguingly, PPARs, initially recognized for their role in lipid metabolism, have emerged as potent modulators of inflammation in autoimmune diseases, particularly in T1D. Although evidence suggests that PPARs affect the β-cell function, their influence on T-cell responses and their potential impact on T1D remains largely unexplored. It was noted that PPARα is involved in restricting the transcription of IL17A and enhancing the expression of Foxp3 by minimizing its proteasomal degradation. Thus, antagonizing PPARs may exert beneficial effects in regulating the differentiation of CD4+ T cells and preventing T1D. Therefore, this review advocates for comprehensive investigations to delineate the precise roles of PPARs in T1D pathogenesis, offering innovative therapeutic avenues that target both the immune system and pancreatic function. This review paper seeks to bridge the knowledge gap between PPARs, immune responses, and T1D, providing insights that may revolutionize the treatment landscape for this autoimmune disorder. Moreover, further studies involving PPAR agonists in non-obese diabetic (NOD) mice hold promise for developing novel T1D therapies.
format Online
Article
Text
id pubmed-10623333
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106233332023-11-04 PPARs at the crossroads of T cell differentiation and type 1 diabetes Riaz, Farooq Wei, Ping Pan, Fan Front Immunol Immunology T-cell-mediated autoimmune type 1 diabetes (T1D) is characterized by the immune-mediated destruction of pancreatic beta cells (β-cells). The increasing prevalence of T1D poses significant challenges to the healthcare system, particularly in countries with struggling economies. This review paper highlights the multifaceted roles of Peroxisome Proliferator-Activated Receptors (PPARs) in the context of T1D, shedding light on their potential as regulators of immune responses and β-cell biology. Recent research has elucidated the intricate interplay between CD4+ T cell subsets, such as Tregs and Th17, in developing autoimmune diseases like T1D. Th17 cells drive inflammation, while Tregs exert immunosuppressive functions, highlighting the delicate balance crucial for immune homeostasis. Immunotherapy has shown promise in reinstating self-tolerance and restricting the destruction of autoimmune responses, but further investigations are required to refine these therapeutic strategies. Intriguingly, PPARs, initially recognized for their role in lipid metabolism, have emerged as potent modulators of inflammation in autoimmune diseases, particularly in T1D. Although evidence suggests that PPARs affect the β-cell function, their influence on T-cell responses and their potential impact on T1D remains largely unexplored. It was noted that PPARα is involved in restricting the transcription of IL17A and enhancing the expression of Foxp3 by minimizing its proteasomal degradation. Thus, antagonizing PPARs may exert beneficial effects in regulating the differentiation of CD4+ T cells and preventing T1D. Therefore, this review advocates for comprehensive investigations to delineate the precise roles of PPARs in T1D pathogenesis, offering innovative therapeutic avenues that target both the immune system and pancreatic function. This review paper seeks to bridge the knowledge gap between PPARs, immune responses, and T1D, providing insights that may revolutionize the treatment landscape for this autoimmune disorder. Moreover, further studies involving PPAR agonists in non-obese diabetic (NOD) mice hold promise for developing novel T1D therapies. Frontiers Media S.A. 2023-10-20 /pmc/articles/PMC10623333/ /pubmed/37928539 http://dx.doi.org/10.3389/fimmu.2023.1292238 Text en Copyright © 2023 Riaz, Wei and Pan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Riaz, Farooq
Wei, Ping
Pan, Fan
PPARs at the crossroads of T cell differentiation and type 1 diabetes
title PPARs at the crossroads of T cell differentiation and type 1 diabetes
title_full PPARs at the crossroads of T cell differentiation and type 1 diabetes
title_fullStr PPARs at the crossroads of T cell differentiation and type 1 diabetes
title_full_unstemmed PPARs at the crossroads of T cell differentiation and type 1 diabetes
title_short PPARs at the crossroads of T cell differentiation and type 1 diabetes
title_sort ppars at the crossroads of t cell differentiation and type 1 diabetes
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623333/
https://www.ncbi.nlm.nih.gov/pubmed/37928539
http://dx.doi.org/10.3389/fimmu.2023.1292238
work_keys_str_mv AT riazfarooq pparsatthecrossroadsoftcelldifferentiationandtype1diabetes
AT weiping pparsatthecrossroadsoftcelldifferentiationandtype1diabetes
AT panfan pparsatthecrossroadsoftcelldifferentiationandtype1diabetes